Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

British Journal of Cancer

Volumn 105, Issue 10, 2011, Pages 1593-1599

  Hofstetter, G ^a   Berger, A ^a   Schuster, E ^b   Wolf, A ^b   Hager, G ^b   Vergote, I ^c   Cadron, I ^c   Sehouli, J ^d   Braicu, E I ^d   Mahner, S ^e   Speiser, P ^b   Marth, C ^a   Zeimet, A G ^a   Ulmer, H ^a   Zeillinger, R ^b   Concin, N ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^c Universitaire Ziekenhuzen Leuven   (Belgium)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

delta133p53; ovarian cancer; p53; p53 isoforms; p73

Indexed keywords

BIOLOGICAL MARKER; DELTA133P53 PROTEIN; PROTEIN P53; PROTEIN P73; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEROUS OVARY CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80755172255     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.433     Document Type: Article

References (32)

1. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, Hersey P (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14: 1659-1668 (Pubitemid 351469449)
2. Bailey SG, Cragg MS, Townsend PA (2011) Family friction as DNp73 antagonises p73 and p53. Int J Biochem Cell Biol 43: 482-486
3. Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, Landi S (2010) DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat 31: 456-465
4. Boldrup L, Bourdon JC, Coates PJ, Sjöström B, Nylander K (2007) Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43: 617-623 (Pubitemid 46177591)
5. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19: 2122-2137 (Pubitemid 41330315)
6. Buhlmann S, Pützer BM (2008) DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 1785: 207-216
7. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529
8. Chen J, Ng SM, Chang C, Zhang Z, Bourdon JC, Lane DP, Peng J (2009) p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev 23: 278-290
9. Chen J, Ruan H, Ng SM, Gao C, Soo HM, Wu W, Zhang Z, Wen Z, Lane DP, Peng J (2005) Loss of function of def selectively up-regulates Delta113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev 19: 2900-2911 (Pubitemid 41739974)
10. Cheok CF, Verma CS, Baselga J, Lane DP (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37
11. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM (2004) Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64: 2449-2460 (Pubitemid 38523899)
12. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R (2005) Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11: 8372-8383 (Pubitemid 41746950)
13. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U, Oren M, Hainaut P (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21: 6722-6728 (Pubitemid 35221914)
14. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101: 149-159
15. Ebrahimi M, Boldrup L, Coates PJ, Wahlin YB, Bourdon JC, Nylander K (2008) Expression of novel p53 isoforms in oral lichen planus. Oral Oncol 44: 156-161 (Pubitemid 351179660)
16. Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24: 7987-7997 (Pubitemid 39167449)
17. Graupner V, Schulze-Osthoff K, Essmann F, Jänicke RU (2009) Functional characterization of p53beta and p53gamma, two isoforms of the tumor suppressor p53. Cell Cycle 8: 1238-1248
18. Jänicke RU, Graupner V, Budach W, Essmann F (2009) The do's and don'ts of p53 isoforms. Biol Chem 390: 951-963
19. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5: e232
20. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY (2006) Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12: 3922-3927 (Pubitemid 44078076)
21. Marabese M, Marchini S, Marrazzo E, Mariani P, Cattaneo D, Fossati R, Compagnoni A, Signorelli M, Moll UM, Codegoni AM, Broggini M (2007) Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer 44: 131-141
22. Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH (2005) TAp73/DNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12: 1564-1577 (Pubitemid 41679162)
23. Murray-Zmijewski F, Lane DP, Bourdon JC (2006) p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 13: 962-972
24. Ohki R, Kawase T, Ohta T, Ichikawa H, Taya Y (2007) Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Sci 98: 189-200 (Pubitemid 44941871)
25. Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107
26. Powell DJ, Hrstka R, Candeias M, Bourougaa K, Vojtesek B, Fähraeus R (2008) Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle 7: 950-959 (Pubitemid 351573791)
27. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG (2007) Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 13: 144-151 (Pubitemid 46121863)
28. Song W, Huo SW, Lü JJ, Liu Z, Fang XL, Jin XB, Yuan MZ (2009) Expression of p53 isoforms in renal cell carcinoma. Chin Med J (Engl) 122: 921-926
29. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K (2004) Expression of DNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10: 6905-6911 (Pubitemid 39383040)
30. Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A (2010) Characterization of DeltaNp73 expression and regulation in gastric and esophageal tumors. Oncogene 28: 5861-5868
31. Winter 3rd WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP (2007) Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627 (Pubitemid 47372600)
32. Yin Y, Stephen CW, Luciani MG, Fähraeus R (2002) p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4: 462-467 (Pubitemid 34746166)